Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 19
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

BRCA1 loss activates cathepsin L-mediated degradation of 53BP1 in breast cancer cells

  • Grotsky, David A.
  • Gonzalez-Suarez, Ignacio
  • Novell, Anna|||0000-0001-6619-8062
  • Neumann, Martin A.
  • Yaddanapudi, Sree C. S.
  • Croke, Monica R.
  • Martinez-Alonso, Montserrat|||0000-0003-1504-8552
  • Redwood, Abena B.
  • Ortega-Martinez, Sylvia
  • Feng, Zhihui
  • Lerma Puertas, Enrique|||0000-0001-7908-2747
  • Ramon y Cajal, Teresa|||0000-0003-3490-3585
  • Zhang, Junran
  • Matías-Guiu, Xavier|||0000-0002-7201-6605
  • Dusso, Ariadna S.
  • Gonzalo, Susana
Loss of 53BP1 rescues BRCA1 deficiency and is associated with BRCA1-deficient and triple-negative breast cancers (TNBC) and with resistance to genotoxic drugs. The mechanisms responsible for decreased 53BP1 transcript and protein levels in tumors remain unknown. Here, we demonstrate that BRCA1 loss activates cathepsin L (CTSL)-mediated degradation of 53BP1. Activation of this pathway rescued homologous recombination repair and allowed BRCA1-deficient cells to bypass growth arrest. Importantly, depletion or inhibition of CTSL with vitamin D or specific inhibitors stabilized 53BP1 and increased genomic instability in response to radiation and poly(adenosine diphosphate-ribose) polymerase inhibitors, compromising proliferation. Analysis of human breast tumors identified nuclear CTSL as a positive biomarker for TNBC, which correlated inversely with 53BP1. Importantly, nuclear levels of CTSL, vitamin D receptor, and 53BP1 emerged as a novel triple biomarker signature for stratification of patients with BRCA1-mutated tumors and TNBC, with potential predictive valuefor drug response. We identify here a novel pathway with prospective relevance for diagnosis and customization of breast cancer therapy. © 2013 Grotsky et al.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

High frequency of CRB1 mutations as cause of Early-Onset Retinal Dystrophies in the Spanish population

  • Corton, Marta|||0000-0003-0087-1626
  • Tatu, Sorina D.
  • Avila-Fernandez, Almudena
  • Vallespín, Elena|||0000-0002-8080-8629
  • Tapias, Ignacio
  • Cantalapiedra, Diego
  • Blanco-Kelly, Fiona|||0000-0003-0052-5651
  • Riveiro-Alvarez, Rosa
  • Bernal, Sara|||0000-0003-4427-0574
  • García-Sandoval, Blanca
  • Baiget Bastús, Montserrat
  • Ayuso, Carmen|||0000-0002-9606-6957
Background: CRB1 mutations are reported as cause of severe congenital and early-onset retinal dystrophies (EORD) with different phenotypic manifestations, including Leber congenital amaurosis (LCA), retinitis pigmentosa (RP) and cone-rod dystrophies. Comprehensive mutational scanning of the whole gene has been only performed in few cohorts, mainly in LCA patients. Here, we aimed investigating the real prevalence of CRB1 mutations in the Spanish population by extensive screening of CRB1 mutations in a large cohort of LCA and EORP cases. Methods. This report integrates data from previous studies on CRB1 defects in our Spanish cohort of LCA and early-onset RP (EORP) with new findings from a comprehensive mutational screening of the whole gene. The molecular tools used include mutation genotyping arrays, whole-genome homozygosity mapping, an optimized high-resolution melting (HRM) analysis and Sanger sequencing. Results: A large clinically well-characterized cohort of 404 Spanish cases was studied, 114 of which suffered from LCA and 290 from EORP. This study reveals that 11% of Spanish patients carried mutations in CRB1, ranging from 9% of EORP to 14% of LCA cases. More than three quarters of the mutations identified herein have been first described in this Spanish cohort, 13 of them are unreported new variants and 13 had been previously reported in our previous studies. Conclusions: This work provides a wide spectrum of CRB1 mutations in the Spanish EORD patients and evidences the major role of CRB1 as causal gene in the Spanish EORP patients. It is noteworthy that a high rate of private mutations only described in our cohort has been found so far. To our knowledge, this study represents the most complete mutational screening of CRB1 in a Spanish LCA and EORP cohort, allowing us to establish gene-specific frequencies and to provide a wide spectrum of CRB1 mutations in the Spanish population. © 2013 Corton et al.; licensee BioMed Central Ltd.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

High RAB25 expression is associated with good clinical outcome in patients with locally advanced head and neck squamous cell carcinoma

  • Téllez-Gabriel, Marta
  • Arroyo Solera, Irene|||0000-0003-0425-1483
  • León i Vintró, Xavier|||0000-0001-6286-630X
  • Gallardo, Alberto|||0000-0002-2514-2027
  • López, Montserrat
  • Céspedes, María Virtudes|||0000-0003-2956-5833
  • Casanova Rigat, Isolda|||0000-0002-1196-4724
  • López Pousa, Antonio|||0000-0003-1066-3951
  • Quer, Miquel|||0000-0003-2563-6729
  • Mangues, Ma Antonia|||0000-0002-1438-8515
  • Barnadas i Molins, Agustí|||0000-0002-0429-1349
  • Mangues, Ramon|||0000-0003-2661-9525
  • Pavón, Miguel A.
Currently there are no molecular markers able to predict clinical outcome in locally advanced head and neck squamous cell carcinoma (HNSCC). In a previous microarray study, RAB25 was identified as a potential prognostic marker. The aim of this study was to analyze the association between RAB25 expression and clinical outcome in patients with locally advanced HNSCC treated with standard therapy. In a retrospective immunohistochemical study (n = 97), we observed that RAB25-negative tumors had lower survival (log-rank, P = 0.01) than patients bearing positive tumors. In an independent prospective mRNA study (n = 117), low RAB25 mRNA expression was associated with poor prognosis. Using classification and regression tree analysis (CART) we established two groups of patients according to their RAB25 mRNA level and their risk of death. Low mRNA level was associated with poor local recurrence-free (log-rank, P = 0.005), progression-free (log-rank, P = 0.002) and cancer-specific (log-rank, P < 0.001) survival. Multivariate Cox model analysis showed that low expression of RAB25 was an independent poor prognostic factor for survival (hazard ratio: 3.84, 95% confidence interval: 1.93-7.62, P < 0.001). Patients whose tumors showed high RAB25 expression had a low probability of death after treatment. We also found lower RAB25 expression in tumors than in normal tissue (Mann-Whitney U, P < 0.001). Moreover, overexpression of RAB25 in the UM-SCC-74B HNSCC cell line increased cisplatin sensitivity, and reduced cell migration and invasion. Our findings support a tumor suppressor role for RAB25 in HNSCC and its potential use to identify locally advanced patients with a high probability of survival after genotoxic treatment. © 2013 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Development and Independent Validation of a Prognostic Gene Expression Signature Based on RB1, PTEN, and TP53 in Metastatic Hormone-sensitive Prostate Cancer Patients

  • Jiménez, Natalia|||0000-0002-7057-0426
  • Garcia de Herreros, Marta
  • Reig, Oscar|||0000-0003-1166-6943
  • Marín Aguilera, Mercedes
  • Aversa, Caterina
  • Ferrer-Mileo, Laura
  • García-Esteve, Samuel|||0000-0002-7680-2048
  • Rodríguez-Carunchio, Leonardo|||0000-0002-7019-554X
  • Trias, Isabel|||0000-0001-9841-4380
  • Font, Albert|||0000-0003-3908-1111
  • Rodriguez-Vida, Alejo|||0000-0002-7304-6857
  • Climent, Miguel Ángel|||0000-0001-7523-0212
  • Cros Costa, Sara|||0000-0001-8279-784X
  • Chirivella, Isabel|||0000-0002-0733-3276
  • Domènech, Montserrat|||0000-0003-3973-0986
  • Figols, Mariona
  • Carles, Joan|||0000-0002-9983-5934
  • Suárez, Cristina|||0000-0002-0502-5528
  • Herrero Rivera, Daniel
  • Gonzalez-Billalabeitia, Enrique|||0000-0003-3143-3143
  • Cívico, Claudia
  • Sala-González, Núria
  • Ruiz de Porras, Vicenç|||0000-0002-4352-1784
  • Ribal, María J.|||0000-0001-8142-5382
  • Prat, Aleix|||0000-0003-2377-540X
  • Mellado, Begoña|||0000-0002-8088-5966
BACKGROUND: Androgen deprivation therapy (ADT) with docetaxel (D) and/or antiandrogen receptor therapies (ARTs) are the standard therapies in metastatic hormone-sensitive prostate cancer (mHSPC). Alterations in the tumor suppressor genes (TSGs) RB1, PTEN, and TP53 are associated with an aggressive evolution and treatment resistance in castration-resistant prostate cancer (CRPC). OBJECTIVE: To study the clinical implications of TSG mRNA expression in mHSPC patients. DESIGN, SETTING, AND PARTICIPANTS: This is a multicenter retrospective biomarker study in mHSPC patients. TSGlow status was defined when two or more out of the three TSGs presented low RNA expression by nCounter in formalin-fixed paraffin-embedded samples and TSGwt for the remaining cases. The microarray data from the CHAARTED trial were analyzed as an independent validation cohort. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Molecular data were correlated with CRPC-free survival (CRPC-FS) and overall survival (OS) by the Kaplan-Meier method and multivariate Cox analysis. RESULTS AND LIMITATIONS: A total of 226 patients were included, of whom 218 were eligible: 93 were treated with ADT and 125 with ADT + D; 75.7% presented de novo stage IV and 67.9% high-volume disease. TSGlow (19.2%) was independently correlated with shorter CRPC-FS (hazard ratio [HR] 1.8, p = 0.002) and OS (HR 2, p = 0.002). In the CHAARTED trial, TSGlow was independently correlated with lower CRPC-FS (HR 2.2, p = 0.02); no differences in clinical outcomes according to treatment were observed in TSGlow patients, while a significant benefit was observed for ADT + D in the TSGwt group for CRPC-FS (HR 0.4, p < 0.001) and OS (HR 0.4, p = 0.001). However, no interaction was observed between TSG signature and treatment in either series. Study limitations are the retrospective design, small sample size, and lack of inclusion of patients treated with ADT + ART. CONCLUSIONS: TSGlow expression correlates with adverse outcomes in patients with mHSPC. The investigation of new therapeutic strategies in these patients is warranted. PATIENT SUMMARY: The low RNA expression of tumor suppressor genes in the tumors is correlated with adverse outcomes in patients with metastatic hormone-sensitive prostate cancer.
Arias Montano. Repositorio Institucional de la Universidad de Huelva
Publicación Artículo científico (JournalArticle)

Colorectal cancer, sun exposure and dietary vitamin D and calcium intake in the MCC-Spain study

  • Vallès, Xavier
  • Henar Alonso, M.
  • López Caleya, Juan Francisco
  • Capelo Álvarez, Rocío
Objectives: To explore the association of colorectal cancer with environmental solar radiation and sun exposure behavior, considering phenotypic variables (eye color, hair color and skin phenotype), dietary intake of vitamin D and calcium, and socio-demographic factors. Study design: Multicenter population-based frequency matched case-control study in Spain (MCC-Spain), with 2140 CRC cases and 3950 controls. Methods: Data were obtained through personal interviews using a structured epidemiological questionnaire that included socio-demographic data, residential history, environmental exposures, behavior, phenotypic and dietary information. An environmental-lifetime sun exposure score was constructed combining residential history and average daily solar radiation, direct and diffuse. Logistic regression was used to explore the association between different variables. A structural equation model was used to verify the associations of the conceptual model. Results: We found a lower risk of CRC in subjects frequently exposed to sunlight during the previous summer and skin burning due to sun exposure. No association was observed in relation to the residential solar radiation scores. Subjects with light eye or light hair colors had a lower risk of CRC that those with darker colors. Dietary calcium and vitamin D were also protective factors, but not in the multivariate model. The structural equation model analysis suggested that higher sun exposure was associated with a decreased risk of CRC, as well as dietary intake of calcium and vitamin D, and these factors are correlated among themselves and with environmental solar radiation and skin phenotypes. Conclusion: The results agree with previous observations that sun exposure, dietary vitamin D and calcium intake, and serum 25(OH)D concentration reduce the risk of CRC and indicate that these factors may be relevant for cancer prevention.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Galectin-1 prevents pathological vascular remodeling in atherosclerosis and abdominal aortic aneurysm

  • Roldán-Montero, R
  • Pérez-Sáez, Juan M.
  • Cerro-Pardo, Isabel
  • Oller, Jorge
  • Martinez-Lopez, Diego
  • Nuñez, Estefania
  • Maller, Sebastian M.
  • Gutierrez-Muñoz, Carmen
  • Mendez-Barbero, Nerea
  • Escola-Gil, Joan C.
  • Michel, Jean-Baptiste
  • Mittelbrunn, Maria
  • Vázquez, Jesús
  • Blanco-Colio, Luis M.
  • Rabinovich, Gabriel A.
  • Martín-Ventura, Jose Luis
Pathological vascular remodeling is the underlying cause of atherosclerosis and abdominal aortic aneurysm (AAA). Here, we analyzed the role of galectin-1 (Gal-1), a β-galactoside-binding protein, as a therapeutic target for atherosclerosis and AAA. Mice lacking Gal-1 (Lgals1-/-) developed severe atherosclerosis induced by pAAV/D377Y-mPCSK9 adenovirus and displayed higher lipid levels and lower expression of contractile markers of vascular smooth muscle cells (VSMCs) in plaques than wild-type mice. Proteomic analysis of Lgals1-/- aortas showed changes in markers of VSMC phenotypic switch and altered composition of mitochondrial proteins. Mechanistically, Gal-1 silencing resulted in increased foam cell formation and mitochondrial dysfunction in VSMCs, while treatment with recombinant Gal-1 (rGal-1) prevented these effects. Furthermore, rGal-1 treatment attenuated atherosclerosis and elastase-induced AAA, leading to higher contractile VSMCs in aortic tissues. Gal-1 expression decreased in human atheroma and AAA compared to control tissue. Thus, Gal-1-driven circuits emerge as potential therapeutic strategies in atherosclerosis and AAA., This study was funded by the Spanish MINECO (PID2019-106814RB-I00 and PGC2018-097019-B-I00), CAM (Complemento II-CM, S2017/BMD-3673), Fondo de Investigaciones Sanitarias ISCiii-FEDER [Biobancos RD09/0076/00101 and PRB3 (IPT17/0019, ProteoRed)], and FEDER “Una manera de hacer Europa.” CIBERCV and CIBERDEM are Instituto de Salud Carlos III projects. This work also received funding from “La Caixa” Banking Foundation under the project code HR17-00247. The CNIC is supported by Instituto de Salud Carlos III (ISCIII), Ministerio de Ciencia, Innovación y Universidades (MCNU), and Pro CNIC Foundation and is a Severo Ochoa Center of Excellence (SEV-2015-0505). Further support was provided by Santander-UAM, Agencia Nacional de Promoción de la Investigación, el Desarrollo Tecnológico y la Innovación (PICT 2010-870, Argentina), Fundación Sales, and Fundación Bunge y Born (Argentina). We thank the support of Ferioli, Ostry, and Caraballo families
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Karyotypic complexity rather than chromosome 8 abnormalities aggravates the outcome of chronic lymphocytic leukemia patients with TP53 aberrations

  • Blanco, Gonzalo|||0000-0001-6557-3764
  • Puiggros, Anna|||0000-0001-9627-4978
  • Baliakas, Panagiotis|||0000-0002-5634-7156
  • Athanasiadou, Anastasia
  • García-Malo, MaDolores
  • Collado, Rosa|||0000-0002-8205-6192
  • Xochelli, Aliki
  • Rodríguez-Rivera, María
  • Ortega, Margarita
  • Calasanz, M.J.|||0000-0002-0374-3008
  • Luño, Elisa
  • Vargas, MªTeresa
  • Grau Cat, Javier
  • Martínez-Laperche, Carolina
  • Valiente, Alberto
  • Cervera, José|||0000-0001-8252-1106
  • Anagnostopoulos, Achilles|||0000-0003-4384-9031
  • Gimeno, Eva|||0000-0002-3534-6189
  • Abella Monreal, Eugenia|||0000-0001-9605-8458
  • Stalika, Evangelia
  • Hernández Rivas, Jesús María|||0000-0002-9661-9371
  • Ortuño, Francisco José|||0000-0003-4450-9346
  • Robles, Diego
  • Ferrer, Ana Maria|||0000-0002-3381-9472
  • Ivars, David
  • González, Marcos
  • Bosch Albareda, Francesc|||0000-0001-9241-2886
  • Abrisqueta, Pau|||0000-0001-9625-7422
  • Stamatopoulos, Kostas|||0000-0001-8529-640X
  • Espinet Solà, Blanca|||0000-0002-4294-8145
Patients with chronic lymphocytic leukemia (CLL) harboring TP53 aberrations (TP53 abs; chromosome 17p deletion and/or TP53 mutation) exhibit an unfavorable clinical outcome. Chromosome 8 abnormalities, namely losses of 8p (8p-) and gains of 8q (8q+) have been suggested to aggravate the outcome of patients with TP53 abs. However, the reported series were small, thus hindering definitive conclusions. To gain insight into this issue, we assessed a series of 101 CLL patients harboring TP53 disruption. The frequency of 8p- and 8q+ was 14.7% and 17.8% respectively. Both were associated with a significantly (P < 0.05) higher incidence of a complex karyotype (CK, ≥3 abnormalities) detected by chromosome banding analysis (CBA) compared to cases with normal 8p (N-8p) and 8q (N-8q), respectively. In univariate analysis for 10-year overall survival (OS), 8p- (P = 0.002), 8q+ (P = 0.012) and CK (P = 0.009) were associated with shorter OS. However, in multivariate analysis only CK (HR = 2.47, P = 0.027) maintained independent significance, being associated with a dismal outcome regardless of chromosome 8 abnormalities. In conclusion, our results highlight the association of chromosome 8 abnormalities with CK amongst CLL patients with TP53 abs, while also revealing that CK can further aggravate the prognosis of this aggressive subgroup.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

MicroRNA-200, associated with metastatic breast cancer, promotes traits of mammary luminal progenitor cells

  • Sánchez-Cid, Lourdes
  • Pons, Mònica
  • Lozano, Juan José
  • Rubio, Nuria
  • Guerra-Rebollo, Marta
  • Soriano, Aroa|||0000-0001-9659-1471
  • Paris-Coderch, Laia
  • Segura, Miquel F.
  • Fueyo Arévalo, Raquel
  • Arguimbau, Judit
  • Zodda, Erika
  • Bermudo, Raquel
  • Alonso, Immaculada
  • Caparrós, Xavier
  • Cascante, Marta
  • Rafii, Arash
  • Kang, Yibin
  • Martínez-Balbás, Marian
  • Weiss, Stephen J.
  • Blanco Fernández, Jerónimo
  • Muñoz, Montserrat
  • Fernández, Pedro Luis|||0000-0002-8618-4597
  • Thomson, Timothy M.
MicroRNAs are critical regulators of gene networks in normal and abnormal biological processes. Focusing on invasive ductal breast cancer (IDC), we have found dysregulated expression in tumor samples of several microRNAs, including the miR-200 family, along progression from primary tumors to distant metastases, further reflected in higher blood levels of miR-200b and miR-7 in IDC patients with regional or distant metastases relative to patients with primary node-negative tumors. Forced expression of miR-200s in MCF10CA1h mammary cells induced an enhanced epithelial program, aldehyde dehydrogenase (ALDH) activity, mammosphere growth and ability to form branched tubuloalveolar structures while promoting orthotopic tumor growth and lung colonization in vivo. MiR-200s also induced the constitutive activation of the PI3K-Akt signaling through downregulation of PTEN, and the enhanced mammosphere growth and ALDH activity induced in MCF10CA1h cells by miR-200s required the activation of this signaling pathway. Interestingly, the morphology of tumors formed in vivo by cells expressing miR-200s was reminiscent of metaplastic breast cancer (MBC). Indeed, the epithelial components of MBC samples expressed significantly higher levels of miR-200s than their mesenchymal components and displayed a marker profile compatible with luminal progenitor cells. We propose that microRNAs of the miR-200 family promote traits of highly proliferative breast luminal progenitor cells, thereby exacerbating the growth and metastatic properties of transformed mammary epithelial cells.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Exposure to disinfection by-products in swimming pools and biomarkers of genotoxicity and respiratory damage - The PISCINA2 Study

  • Font Ribera, Laia|||0000-0001-8447-4905
  • Marco, Esther
  • Grimalt, Joan|||0000-0002-7391-5768
  • Pastor Benito, Susana|||0000-0003-2454-5163
  • Marcos, Ricard|||0000-0001-7891-357X
  • Abramsson-Zetterberg, Lilianne
  • Pedersen, Marie
  • Grummt, Tamara
  • Junek, Ralf
  • Barreiro, Esther|||0000-0003-2708-3443
  • Heederik, Dick
  • Spithoven, Jack
  • Critelli, Rossana
  • Naccarati, Alessio
  • Schmalz, Christina
  • Zwiener, Christian
  • Liu, Jiaqi
  • Zhang, Xiangru
  • Mitch, William
  • Gracia-Lavedan, Esther
  • Arjona, Lourdes
  • De Bont, Jeroen|||0000-0001-9924-5961
  • Tarès, Lluïsa
  • Vineis, Paolo
  • Kogevinas, Manolis|||0000-0002-9605-0461
  • Villanueva, Cristina|||0000-0002-0783-1259
Background: Swimming in pools is a healthy activity that entails exposure to disinfection by-products (DBPs), some of which are irritant and genotoxic. Objectives: We evaluated exposure to DBPs during swimming in a chlorinated pool and the association with short-term changes in genotoxicity and lung epithelium permeability biomarkers. Methods: Non-smoker adults (N = 116) swimming 40 min in an indoor pool were included. We measured a range of biomarkers before and at different times after swimming: trihalomethanes (THMs) in exhaled breath (5 min), trichloroacetic acid (TCAA) in urine (30 min), micronuclei in lymphocytes (1 h), serum club cell protein (CC16) (1 h), urine mutagenicity (2 h) and micronuclei in reticulocytes (4 days in a subset, N = 19). Several DBPs in water and trichloramine in air were measured, and physical activity was extensively assessed. We estimated interactions with polymorphisms in genes related to DBP metabolism. Results: Median level of chloroform, brominated and total THMs in water was 37.3, 9.5 and 48.5, μg/L, respectively, and trichloramine in air was 472.6 μg/m. Median exhaled chloroform, brominated and total THMs increased after swimming by 10.9, 2.6 and 13.4, μg/m, respectively. Creatinine-adjusted urinary TCAA increased by 3.1 μmol/mol. Micronuclei in lymphocytes and reticulocytes, urine mutagenicity and serum CC16 levels remained unchanged after swimming. Spearman correlation coefficients showed no association between DBP exposure and micronuclei in lymphocytes, urine mutagenicity and CC16. Moderate associations were observed for micronuclei in reticulocytes and DBP exposure. Conclusions: The unchanged levels of the short-term effect biomarkers after swimming and null associations with personal estimates of exposure to DBPs suggest no measurable effect on genotoxicity in lymphocytes, urine mutagenicity and lung epithelium permeability at the observed exposure levels. The moderate associations with micronuclei in reticulocytes require cautious interpretation given the reduced sample size.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Diagnostic accuracy of non-melanocytic pink flat skin lesions on the legs, Dermoscopic and reflectance confocal microscopy evaluation

  • Gómez Martín, Ignacio
  • Moreno Fernández, Sara
  • Duran-Jordà, Xavier|||0000-0001-8517-9254
  • Pujol Vallverdú, Ramón M.|||0000-0002-5622-6055
  • Segura, Sonia|||0000-0003-0653-1382
Pink flat skin lesions on the legs in elderly people represent a diagnostic challenge due to the paucity of clinical and dermoscopic evidence. A prospective study of 114 pink flat lesions on the legs of 85 elderly patients was performed to describe the utility of reflectance confocal microscopy in this clinical context. Evaluation of clinical, dermoscopic and confocal parameters and calculation of diagnostic accuracy/sensi-tivity/specificity for non-melanoma skin cancer diagnosis of each technique were carried out. Thirty-four benign and 80 malignant neoplasms were analysed. A correct clinical diagnosis was established in 49.1% of cases (sensitivity 68.7%, specificity 73.5%). Dermoscopy achieved 59.6% correct diagnosis (sensiti-vity 85%, specificity 67.6%) and confocal microscopy evaluation after clinical and dermoscopic evaluation rendered a correct diagnosis in 85.1% of cases (sensi-tivity 97.5%, specificity 88.2%). Confocal microscopy may improve diagnostic accuracy, sensitivity and specificity as a secondary evaluation after dermoscopy. A diagnostic confocal algorithm for pink flat lesions on the legs is proposed.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

APOA1 oxidation is associated to dysfunctional high-density lipoproteins in human abdominal aortic aneurysm

  • Martínez-López, Diego
  • Camafeita, Emilio|||0000-0002-4577-5331
  • Cedó, Lídia|||0000-0003-4354-3411
  • Roldán-Montero, Raquel|||0000-0003-0117-2608
  • Jorge, Inmaculada
  • García-Marqués, Fernando
  • Gómez-Serrano, María
  • Bonzon-Kulichenko, Elena|||0000-0003-0852-7520
  • Blanco Vaca, Francisco|||0000-0001-7380-5385
  • Blanco-Colio, Luis Miguel|||0000-0002-1560-6609
  • Michel, Jean-Baptiste
  • Escolà-Gil, Joan Carles|||0000-0001-9021-2485
  • Vázquez, Jesús|||0000-0003-1461-5092
  • Martin-Ventura, Jose Luis
High-density lipoproteins (HDL) are a complex mixture of lipids and proteins with vasculoprotective properties. However, HDL components could suffer post-translational modifications (PTMs) under pathological conditions, leading to dysfunctional HDL. We studied whether HDL are modified in abdominal aortic aneurysm (AAA) and the effect on HDL functionality. HDL were isolated by ultracentrifugation from AAA tissue (HDL-T) and from plasma of healthy volunteers and then incubated with AAA tissue-conditioned medium (HDL-AAA CM). PTMs from these particles were characterized using Comet-PTM. The ability of HDL-AAA CM for promoting cholesterol efflux was determined ex vivo and in vivo by using J774A.1 [ 3 H]cholesterol-labeled mouse macrophages and after injecting [ 3 H]cholesterol-labeled mouse macrophages and HDL into the peritoneal cavity of wild-type C57BL/6 mice, respectively. Trp50 and Trp108 oxidized forms of APOA1 in HDL incubated with conditioned-medium of activated neutrophils and in plasma of AAA patients and controls were measured by targeted parallel reaction monitoring. Oxidation was the most prevalent PTM in apolipoproteins, particularly in APOA1. Trp50 and Trp108 in APOA1 were the residues most clearly affected by oxidation in HDL-T and in HDL-AAA CM, when compared to their controls. In addition, cholesterol efflux was decreased in macrophages incubated with HDL-AAA CM in vitro and a decreased macrophage-to-serum reverse cholesterol transport was also observed in mice injected with HDL-AAA CM. Finally, both oxidized Trp50 and Trp108 forms of APOA1 were increased in HDL incubated with conditioned-medium of activated neutrophils and in plasma of AAA patients in relation to controls. Oxidative modifications of HDL present in AAA tissue and plasma were closely associated with the loss of vasculoprotective properties of HDL in AAA. MINECO, ISCiii-FEDER, CIBERDEM, CIBERCV and LA CAIXA.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

MiR-204 silencing in intraepithelial to invasive cutaneous squamous cell carcinoma progression

  • Toll Abelló, Agustí|||0000-0003-2656-0076
  • Salgado Sánchez, Rocío Nieves|||0000-0003-1678-8982
  • Espinet Solà, Blanca|||0000-0002-4294-8145
  • Diaz-Lagares, Angel|||0000-0002-9114-9227
  • Hernández-Ruiz, Eugenia
  • Andrades, Evelyn|||0000-0003-2166-6760
  • Sandoval, Juan|||0000-0002-5100-973X
  • Esteller, M.|||0000-0003-4490-6093
  • Pujol, Ramón M..
  • Hernández-Muñoz, Inmaculada
Cutaneous squamous cell carcinoma (cSCC) is the second most common skin cancer and frequently progresses from an actinic keratosis (AK), a sun-induced keratinocyte intraepithelial neoplasia (KIN). Epigenetic mechanisms involved in the phenomenon of progression from AK to cSCC remain to be elicited. Expression of microRNAs in sun-exposed skin, AK and cSCC was analysed by Agilent microarrays. DNA methylation of miR-204 promoter was determined by bisulphite treatment and pyrosequencing. Identification of miR-204 targets and pathways was accomplished in HaCat cells. Immunofluorescence and immunohistochemistry were used to analyze STAT3 activation and PTPN11 expression in human biopsies. cSCCs display a marked downregulation of miR-204 expression when compared to AK. DNA methylation of miR-204 promoter was identified as one of the repressive mechanisms that accounts for miR-204 silencing in cSCC. In HaCaT cells miR-204 inhibits STAT3 and favours the MAPK signaling pathway, likely acting through PTPN11, a nuclear tyrosine phosphatase that is a direct miR-204 target. In non-peritumoral AK lesions, activated STAT3, as detected by pY705-STAT3 immunofluorescence, is retained in the membrane and cytoplasm compartments, whereas AK lesions adjacent to cSCCs display activated STAT3 in the nuclei. Our data suggest that miR-204 may act as a "rheostat" that controls the signalling towards the MAPK pathway or the STAT3 pathway in the progression from AK to cSCC. The online version of this article (doi:10.1186/s12943-016-0537-z) contains supplementary material, which is available to authorized users.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Phosphorylation of eIF4E Confers Resistance to Cellular Stress and DNA-Damaging Agents through an Interaction with 4E-T, A Rationale for Novel Therapeutic Approaches

  • Martínez, Alba
  • Sesé, Marta|||0000-0003-1473-4833
  • Hernandez-Losa, Javier|||0000-0003-1526-3201
  • Robichaud, Nathaniel
  • Sonenberg, Nahum
  • Aasen, Trond|||0000-0003-0763-2695
  • Ramón y Cajal, Santiago|||0000-0002-3867-1390
Phosphorylation of the eukaryotic translation initiation factor eIF4E is associated with malignant progression and poor cancer prognosis. Accordingly, here we have analyzed the association between eIF4E phosphorylation and cellular resistance to oxidative stress, starvation, and DNA-damaging agents in vitro. Using immortalized and cancer cell lines, retroviral expression of a phosphomimetic (S209D) form of eIF4E, but not phospho-dead (S209A) eIF4E or GFP control, significantly increased cellular resistance to stress induced by DNA-damaging agents (cisplatin), starvation (glucose+glutamine withdrawal), and oxidative stress (arsenite). De novo accumulation of eIF4E-containing cytoplasmic bodies colocalizing with the eIF4E-binding protein 4E-T was observed after expression of phosphomimetic S209D, but not S209A or wild-type eIF4E. Increased resistance to cellular stress induced by eIF4E-S209D was lost upon knockdown of endogenous 4E-T or use of an eIF4E-W73A-S209D mutant unable to bind 4E-T. Cancer cells treated with the Mnk1/2 inhibitor CGP57380 to prevent eIF4E phosphorylation and mouse embryonic fibroblasts derived from Mnk1/2 knockout mice were also more sensitive to arsenite and cisplatin treatment. Polysome analysis revealed an 80S peak 2 hours after arsenite treatment in cells overexpressing phosphomimetic eIF4E, indicating translational stalling. Nonetheless, a selective increase was observed in the synthesis of some proteins (cyclin D1, HuR, and Mcl-1). We conclude that phosphorylation of eIF4E confers resistance to various cell stressors and that a direct interaction or regulation of 4E-T by eIF4E is required. Further delineation of this process may identify novel therapeutic avenues for cancer treatment, and these results support the use of modern Mnk1/2 inhibitors in conjunction with standard therapy.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

HPV Testing by cobas HPV Test in a Population from Catalonia

  • Lloveras, Belen|||0000-0001-8659-5241
  • Gomez, Silvia
  • Alameda, Francesc|||0000-0002-7302-6901
  • Bellosillo Paricio, Beatriz|||0000-0002-5335-2726
  • Mojal, Sergi|||0000-0003-0523-3869
  • Muset, Mercè
  • Parra, Manuel
  • Palomares, José Carlos
  • Serrano, Sergi
HPV testing in cervical cancer screening has been proposed as an alternative or complementary to cytology in women older than 30 years. However, adequate clinical sensitivity and specificity are crucial for a new test to be implemented. Hybrid Capture 2 (HC2) has proved good clinical performance in selecting women at risk for high-grade intraepithelial lesions with a high sensitivity and specificity. cobas HPV Test has been recently launched and its performance in different clinical settings needs to be determined. The aim of this study was to evaluate the cobas HPV Test for the detection of cervical HPV infection in a population of women in Catalonia (Spain) using HC2 as a reference. Cervical liquid cytology samples from 958 women have been studied. Sensitivity was analyzed in 60 samples from patients with a high-grade intraepithelial lesion (≥CIN2) on histology and specificity was determined in 898 samples from women with no ≥CIN2. All cases had HC2 and cobas HPV Test performed. Statistical analyses of sensitivity, specificity and comparison between HC2 and cobas HPV Test by a non-inferiority test were applied. Sensitivity of HC2 and cobas HPV Test for detecting ≥CIN2 proved identical (98.3%) while specificity was 85.3% and 86.2% respectively. The non-inferiority test demonstrated that cobas HPV Test surpassed 90% sensitivity and 98% specificity of HC2. The cobas HPV Test results fulfilled sensitivity and specificity requirements for HPV based cervical cancer screening and for the triage of minor cytological abnormalities, allowing its introduction in clinical settings.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Galectin-1 prevents pathological vascular remodeling in atherosclerosis and abdominal aortic aneurysm

  • Roldán-Montero, Raquel|||0000-0003-0117-2608
  • Pérez-Sáez, Juan M.|||0000-0002-6722-5760
  • Cerro-Pardo, Isabel|||0000-0002-2542-5051
  • Oller Pedrosa, Jorge|||0000-0002-2224-2954
  • Martínez-López, Diego
  • Nuñez, Estefania|||0000-0002-0876-1264
  • Maller, Sebastian M.|||0000-0001-5536-7596
  • Gutiérrez Muñoz, Carmen|||0000-0001-8975-6135
  • Mendez-Barbero, Nerea|||0000-0003-1620-3067
  • Escolà-Gil, Joan Carles|||0000-0001-9021-2485
  • Michel, Jean-Baptiste
  • Mittelbrunn, Maria|||0000-0003-3487-8762
  • Vázquez, Jesús|||0000-0003-1461-5092
  • Blanco-Colio, Luis Miguel|||0000-0002-1560-6609
  • Rabinovich, Gabriel A.|||0000-0002-0947-8735
  • Martin-Ventura, Jose L.|||0000-0003-2090-8641
Pathological vascular remodeling is the underlying cause of atherosclerosis and abdominal aortic aneurysm (AAA). Here, we analyzed the role of galectin-1 (Gal-1), a β-galactoside-binding protein, as a therapeutic target for atherosclerosis and AAA. Mice lacking Gal-1 (Lgals1 -/- ) developed severe atherosclerosis induced by pAAV/D377Y-mPCSK9 adenovirus and displayed higher lipid levels and lower expression of contractile markers of vascular smooth muscle cells (VSMCs) in plaques than wild-type mice. Proteomic analysis of Lgals1 -/- aortas showed changes in markers of VSMC phenotypic switch and altered composition of mitochondrial proteins. Mechanistically, Gal-1 silencing resulted in increased foam cell formation and mitochondrial dysfunction in VSMCs, while treatment with recombinant Gal-1 (rGal-1) prevented these effects. Furthermore, rGal-1 treatment attenuated atherosclerosis and elastase-induced AAA, leading to higher contractile VSMCs in aortic tissues. Gal-1 expression decreased in human atheroma and AAA compared to control tissue. Thus, Gal-1-driven circuits emerge as potential therapeutic strategies in atherosclerosis and AAA. Galectin-1 plays an essential role in prevention of atherosclerosis and abdominal aortic aneurysm.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Malondialdehyde-modified HDL particles elicit a specific IgG response in abdominal aortic aneurysm

  • Rodríguez-Carrio, J.
  • Cerro-Pardo, Isabel|||0000-0002-2542-5051
  • Lindholt, Jes S.|||0000-0001-9536-4488
  • Bonzon-Kulichenko, Elena|||0000-0003-0852-7520
  • Martínez-López, Diego
  • Roldán-Montero, R.
  • Escolà-Gil, Joan Carles|||0000-0001-9021-2485
  • Michel, J.B.
  • Blanco-Colio, Luis Miguel|||0000-0002-1560-6609
  • Vázquez, Jesús|||0000-0003-1461-5092
  • Suárez, A.
  • Martín-Ventura, J.L.
High Density Lipoprotein (HDL) plays a protective role in abdominal aortic aneurysm (AAA); however, recent findings suggest that oxidative modifications could lead to dysfunctional HDL in AAA. This study aimed at testing the effect of oxidized HDL on aortic lesions and humoral immune responses in a mouse model of AAA induced by elastase, and evaluating whether antibodies against modified HDL can be found in AAA patients. HDL particles were oxidized with malondialdehyde (HDL-MDA) and the changes were studied by biochemical and proteomics approaches. Experimental AAA was induced in mice by elastase perfusion and then mice were treated with HDL-MDA, HDL or vehicle for 14 days. Aortic lesions were studied by histomorphometric analysis. Levels of anti-HDL-MDA IgG antibodies were measured by an in-house immunoassay in the mouse model, in human tissue-supernatants and in plasma samples from the VIVA cohort. HDL oxidation with MDA was confirmed by enhanced susceptibility to diene formation. Proteomics demonstrated the presence of MDA adducts on Lysine residues of HDL proteins, mainly ApoA-I. MDA-modification of HDL abrogated the protective effect of HDL on cultured endothelial cells as well as on AAA dilation in mice. Exposure to HDL-MDA elicited an anti-HDL-MDA IgG response in mice. Anti-HDL-MDA were also detected in tissue-conditioned media from AAA patients, mainly in intraluminal thrombus. Higher plasma levels of anti-HDL-MDA IgG antibodies were found in AAA patients compared to controls. Anti-HDL-MDA levels were associated with smoking and were independent predictors of overall mortality in AAA patients. Overall, MDA-oxidized HDL trigger a specific humoral immune response in mice. Besides, antibodies against HDL-MDA can be detected in tissue and plasma of AAA patients, suggesting its potential use as surrogate stable biomarkers of oxidative stress in AAA.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

p53 wild-type colorectal cancer cells that express a fetal gene signature are associated with metastasis and poor prognosis

  • Solé Font, Laura|||0000-0002-3195-0565
  • Lobo-Jarne, Teresa|||0000-0002-1632-438X
  • Álvarez-Villanueva, Daniel
  • Alonso-Marañón, Josune
  • Guillén, Yolanda|||0000-0001-8673-6470
  • Guix, Marta|||0000-0002-2143-0697
  • Sangrador, Irene
  • Rozalén, Catalina
  • Vert, Anna
  • Barbachano, Antonio|||0000-0002-1248-5143
  • Lop Gros, Joan|||0000-0002-9442-5688
  • Salido, Marta|||0000-0001-9988-5977
  • Bellosillo Paricio, Beatriz|||0000-0002-5335-2726
  • García-Romero, Raquel
  • Garrido, Marta
  • González Miranda, Jessica|||0000-0001-7732-1564
  • Martínez-Iniesta, María
  • López-Arribillaga, Erika|||0000-0002-9451-6635
  • Salazar, Ramón
  • Torres, Ferran|||0000-0002-7355-7913
  • Iglesias, Mar|||0000-0002-2274-4671
  • Celià-Terrassa, Toni|||0000-0002-0615-8744
  • Muñoz, Alberto|||0000-0003-3890-4251
  • Villanueva, Alejandro|||0000-0001-5164-0006
  • Bigas Salvans, Anna|||0000-0003-4801-6899
  • Espinosa, Lluis|||0000-0002-2897-4099
Current therapy against colorectal cancer (CRC) is based on DNA-damaging agents that remain ineffective in a proportion of patients. Whether and how non-curative DNA damage-based treatment affects tumor cell behavior and patient outcome is primarily unstudied. Using CRC patient-derived organoids (PDO)s, we show that sublethal doses of chemotherapy (CT) does not select previously resistant tumor populations but induces a quiescent state specifically to TP53 wildtype (WT) cancer cells, which is linked to the acquisition of a YAP1-dependent fetal phenotype. Cells displaying this phenotype exhibit high tumor-initiating and metastatic activity. Nuclear YAP1 and fetal traits are present in a proportion of tumors at diagnosis and predict poor prognosis in patients carrying TP53 WT CRC tumors. We provide data indicating the higher efficacy of CT together with YAP1 inhibitors for eradication of therapy resistant TP53 WT cancer cells. Together these results identify fetal conversion as a useful biomarker for patient prognosis and therapy prescription.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Evidence in chronic kidney disease-mineral and bone disorder guidelines, Is it time to treat or time to wait?

  • Bover, Jordi|||0000-0003-3577-2273
  • Ureña-Torres, Pablo|||0000-0001-6757-1906
  • Mateu, Silvia
  • DaSilva Santos, Iara|||0000-0001-8203-6135
  • Gràcia, Silvia
  • Sánchez-Baya, Maya|||0000-0003-1689-9383
  • Arana Aliaga, Carolt|||0000-0003-1100-5758
  • Fayos de Arizón, Leonor|||0000-0002-9277-645X
  • Guirado, Luis|||0000-0001-5119-3912
  • Cozzolino, Mario|||0000-0002-8494-6252
Chronic kidney disease-mineral and bone disorder (CKD-MBD) is one of the many important complications associated with CKD and may at least partially explain the extremely high morbidity and mortality among CKD patients. The 2009 Kidney Disease: Improving Global Outcomes (KDIGO) Clinical Practice Guideline document was based on the best information available at that time and was designed not only to provide information but also to assist in decision-making. In addition to the international KDIGO Work Group, which included worldwide experts, an independent Evidence Review Team was assembled to ensure rigorous review and grading of the existing evidence. Based on the evidence from new clinical trials, an updated Clinical Practice Guideline was published in 2017. In this review, we focus on the conceptual and practical evolution of clinical guidelines (from eMinence-based medicine to eVidence-based medicine and 'living' guidelines), highlight some of the current important CKD-MBD-related changes, and underline the poor or extremely poor level of evidence present in those guidelines (as well as in other areas of nephrology). Finally, we emphasize the importance of individualization of treatments and shared decision-making (based on important ethical considerations and the 'best available evidence'), which may prove useful in the face of the uncertainty over the decision whether 'to treat' or 'to wait'.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

A saturated map of common genetic variants associated with human height

  • Yengo, Loic|||0000-0002-4272-9305
  • Vedantam, Sailaja|||0000-0003-3892-7461
  • Marouli, Eirini|||0000-0001-6179-1609
  • Sidorenko, Julia
  • Bartell, Eric
  • Sakaue, Saori|||0000-0003-3618-9717
  • Graff, Marielisa
  • Eliasen, Anders U.
  • Jiang, Yunxuan
  • Raghavan, Sridharan
  • Miao, Jenkai
  • Arias, Joshua D.
  • Graham, Sarah E.|||0000-0003-1271-2489
  • Mukamel, Ronen E.
  • Spracklen, Cassandra N.|||0000-0003-3590-7182
  • Yin, Xianyong|||0000-0001-6454-2384
  • Chen, Shyh-Huei
  • Ferreira, Teresa
  • Highland, Heather H.
  • Ji, Yingjie
  • Karaderi, Tugce|||0000-0001-9763-8139
  • Lin, Kuang
  • Lüll, Kreete
  • Malden, Deborah|||0000-0003-0567-8294
  • Medina-Gomez, Carolina|||0000-0001-7999-5538
  • Machado, Moara
  • Moore, Amy
  • Rüeger, Sina
  • Sim, Xueling|||0000-0002-1233-7642
  • Vrieze, Scott
  • Ahluwalia, Tarunveer Singh|||0000-0002-7464-3354
  • Akiyama, Masato|||0000-0002-1879-5476
  • Allison, Matthew A.
  • Álvarez, Marcus
  • Andersen, Mette korre|||0000-0001-8227-1469
  • Ani, Alireza|||0000-0002-7868-3118
  • Appadurai, Vivek
  • Arbeeva, Liubov|||0000-0001-5004-419X
  • Bhaskar, Seema
  • Bielak, Lawrence F.|||0000-0002-3443-8030
  • Bollepalli, Sailalitha|||0000-0002-8773-7149
  • Bonnycastle, Lori L.
  • Bork-Jensen, Jette
  • Bradfield, Jonathan Paul|||0000-0001-8758-2071
  • Bradford, Yuki
  • Braund, Peter S.|||0000-0001-8540-5709
  • Brody, Jennifer A.|||0000-0001-8509-148X
  • Burgdorf, Kristoffer S.
  • Cade, Brian E.|||0000-0003-1424-0673
  • Cai, H.
  • Cai, Qiuyin
  • Campbell, Archie|||0000-0003-0198-5078
  • Cañadas-Garre, Marisa|||0000-0003-1103-5658
  • Catamo, Eulalia|||0000-0002-4701-9134
  • Chai, Jin-Fang|||0000-0003-3770-1137
  • Chai, Xiaoran
  • Chang, Liching
  • Chang, Yicheng
  • Chen, Chien Hsiun
  • Chesi, Alessandra|||0000-0002-0954-7446
  • Choi, Seunghoan
  • Chung, Renhua
  • Cocca, Massimiliano|||0000-0002-1127-7596
  • Concas, Maria Pina|||0000-0003-3598-2537
  • Couture, Christian Y.
  • Cuellar-Partida, Gabriel|||0000-0001-7648-4097
  • Danning, Rebecca D.
  • Daw, E. Warwick
  • Degenhard, Frauke
  • Delgado, Graciela E.|||0000-0002-1272-7210
  • Delitala, Alessandro|||0000-0003-1729-8969
  • Demirkan, Ayşe|||0000-0002-7546-0867
  • Deng, Xuan|||0000-0003-0918-817X
  • Devineni, Poornima
  • Dietl, Alexander|||0000-0002-4091-8620
  • Dimitriou, Maria E.
  • Dimitrov, Latchezar M.
  • Dorajoo, Rajkumar|||0000-0001-6608-2051
  • Ekici, Arif B.
  • Engmann, Jorgen|||0000-0001-7015-7773
  • Fairhurst-Hunter, Zammy
  • Farmaki, Aliki Eleni
  • Faul, Jessica D.|||0000-0002-6969-6478
  • Fernandez-Lopez, Juan Carlos|||0000-0003-3680-4193
  • Forer, Lukas|||0000-0003-2139-7329
  • Francescatto, Margherita
  • Freitag-Wolf, Sandra
  • Fuchsberger, Christian|||0000-0002-5918-8947
  • Galesloot, Tessel E.
  • Gao, Yan
  • Gao, Zishan|||0000-0003-1299-0286
  • Geller, Frank
  • Giannakopoulou, Olga
  • Giulianini, Franco
  • Gjesing, Anette Prior
  • Goel, Anuj|||0000-0003-2307-4021
  • Gordon, Scott D.|||0000-0001-7623-328X
  • Gorski, Mathias M.
  • Grove, Jakob|||0000-0003-2284-5744
  • Guo, Xiuqing
  • Gustafsson, S.|||0000-0001-5894-0351
  • Haessler, Jeffrey W.
  • Hansen, Thomas Folkmann
  • Havulinna, Aki Samuli
  • Haworth, S.J.
  • He, Jing
  • Heard-Costa, Nancy L.
  • Hebbar, Prashantha|||0000-0001-6560-7063
  • Hindy, George|||0000-0002-7257-9299
  • Ho, Yuk Lam Anne
  • Hofer, Edith
  • Holliday, Elizabeth|||0000-0002-4066-6224
  • Horn, Katrin
  • Hornsby, Whitney E.
  • Hottenga, Jouke Jan|||0000-0002-5668-2368
  • Huang, Hongyan
  • Huang, Jie
  • Huerta-Chagoya, Alicia|||0000-0001-6218-3904
  • Huffman, Jennifer E.|||0000-0002-9672-2491
  • Hung, Yijen
  • Huo, Shaofeng
  • Hwang, Mi-yeong
  • Iha, Hiroyuki|||0000-0003-4261-2067
  • Ikeda, Daisuke D.|||0000-0001-8403-0327
  • Isono, Masato
  • Jackson, Anne U.|||0000-0002-9672-2547
  • Jäger, Susanne
  • Jansen, Iris E.|||0000-0003-1901-8131
  • Johansson, Ingegerd
  • Jonas, Jost Bruno
  • Jonsson, Anna Elisabet
  • Jørgensen, Torben J.
  • Kalafati, IP.|||0000-0001-5572-7491
  • Kanai, Masahiro|||0000-0001-5165-4408
  • Kanoni, Stavroula|||0000-0002-1691-9615
  • Kårhus, Line Lund
  • Kasturiratne, Anuradhani
  • Katsuya, Tomohiro|||0000-0002-8892-8828
  • Kawaguchi, Takahisa
  • Kember, Rachel L.|||0000-0001-8820-2659
  • Kentistou, Katherine A.|||0000-0002-5816-664X
  • Kim, Hanna
  • Kim, Young-jin
  • Kleber, Marcus Edi
  • Knol, Maria J.|||0000-0002-3597-1531
  • Kurbasic, Azra
  • Lauzon, Marie
  • Le, Phuong
  • Lea, Rodney A.
  • Lee, Jongyoung
  • Leonard, Hampton L.|||0000-0003-2390-8110
  • Li, Shengchao Alfred
  • Li, Xiaoyin
  • Liang, Jingjing
  • Lin, Honghuang
  • Lin, Shihyi
  • Liu, Jun|||0000-0001-5288-3042
  • Liu, Xueping
  • Lo, Ken Sin
  • Long, Jirong
  • Lores-Motta, Laura
  • Luan, Jian'fan N. An
  • Lyssenko, Valeriya
  • Lyytikäinen, Leo Pekka
  • Mahajan, Anubha|||0000-0001-5585-3420
  • Mamakou, Vasiliki
  • Mangino, Massimo
  • Manichaikul, Ani W.
  • Marten, Jonathan|||0000-0001-6916-2014
  • Mattheisen, Manuel|||0000-0002-8442-493X
  • Mavarani, Laven
  • McDaid, Aaron F.
  • Meidtner, Karina
  • Melendez, Tori L.
  • Mercader, Josep M.|||0000-0001-8494-3660
  • Milaneschi, Yuri|||0000-0002-3697-6617
  • Miller, Jason E.
  • Millwood, Iona Y.
  • Mishra, Pashupati P.|||0000-0001-5177-3431
  • Mitchell, Ruth E.
  • Møllehave, Line Tang|||0000-0001-7116-9346
  • Morgan, Anna
  • Mucha, Soeren
  • Munz, Matthias|||0000-0002-4728-3357
  • Nakatochi, Masahiro|||0000-0002-1838-4837
  • Nelson, Christopher P.
  • Nethander, Maria
  • Nho, Chu Won
  • Nielsen, Aneta A.
  • Nolte, Ilja M.|||0000-0001-5047-4077
  • Nongmaithem, Suraj S.|||0000-0001-5390-0449
  • Noordam, Raymond|||0000-0001-7801-809X
  • Ntalla, Ioanna
  • Nutile, Teresa
  • Pandit, Anita
  • Christofidou, Paraskevi
  • Pärna, Katri
  • Pauper, Marc
  • Petersen, Eva R.B.
  • Petersen, Liselotte V.
  • Pitkänen, Niina
  • Polašek, Ozren
  • Poveda, Alaitz|||0000-0001-6349-3955
  • Preuss, Michael H.
  • Pyarajan, Saiju
  • Raffield, Laura M.
  • Rakugi, Hiromi
  • Ramirez, Julia
  • Rasheed, Asif
  • Raven, Dennis
  • Rayner, Nigel W.
  • Riveros, Carlos
  • Rohde, Rebecca
  • Ruggiero, Daniela|||0000-0003-3898-7827
  • Ruotsalainen, Sanni E.|||0000-0002-1631-4069
  • Ryan, Kathleen A.
  • Sabater-Lleal, Maria|||0000-0002-0128-379X
  • Saxena, Richa
  • Scholz, Markus|||0000-0002-4059-1779
  • Sendamarai, Anoop
  • Shen, Botong
  • Shi, Jingchunzi
  • Shin, J.H.
  • Sidore, Carlo|||0000-0001-7504-7477
  • Sitlani, Collen M.|||0000-0001-7656-7482
  • Slieker, Roderick C.
  • Smit, Roelof A. J.
  • Smith, Albert V.
  • Smith, Jennifer A.|||0000-0002-3575-5468
  • Smyth, Laura J.|||0000-0001-6419-4826
  • Southam, Lorraine
  • Steinthorsdottir, Valgerdur
  • Sun, Liang
  • Takeuchi, Fumihiko
  • Tallapragada, Divya Sri Priyanka
  • Taylor, Kent|||0000-0002-2756-4370
  • Tayo, Bamidele O.
  • Tcheandjieu, Catherine
  • Terzikhan, Natalie
  • Tesolin, Paola|||0000-0002-5238-6422
  • Teumer, Alexander|||0000-0002-8309-094X
  • Theusch, Elizabeth|||0000-0002-5678-759X
  • Thompson, Deborah J.
  • Thorleifsson, Gudmar|||0000-0003-4623-9087
  • Timmers, Paul R. H. J.
  • Trompet, Stella|||0000-0001-5006-0528
  • Turman, Constance
  • Vaccargiu, Simona
  • van der Laan, Sander W.|||0000-0001-6888-1404
  • van der Most, Peter J.|||0000-0001-8450-3518
  • van Klinken, Jan Bert
  • van Setten, Jessica A.
  • Verma, Shefali Setia
  • Verweij, Niek|||0000-0002-4303-7685
  • Veturi, Yogasudha C.
  • Wang, Carol A.|||0000-0002-4301-3974
  • Wang, Chaolong
  • Wang, Lihua
  • Wang, Zhe|||0000-0003-0786-9887
  • Warren, Helen R.
  • Bin Wei, Wen
  • Wickremasinghe, Ananda|||0000-0002-6174-6784
  • Wielscher, Matthias|||0000-0003-4138-1383
  • Wiggins, Kerri L.|||0000-0003-2749-1279
  • Winsvold, Bendik Slagsvold|||0000-0003-4171-8919
  • Wong, Andrew|||0000-0003-2079-4779
  • Wu, Yang|||0000-0002-0128-7280
  • Wuttke, Matthias|||0000-0003-3420-5082
  • Xia, Rui|||0000-0003-2409-1181
  • Xie, Tian
  • Yamamoto, Ken
  • Yang, Jingyun
  • Yao, Jie
  • Young, Hannah|||0000-0002-4248-9612
  • Yousri, Noha A.|||0000-0003-1918-0331
  • Yu, Lei
  • Zeng, Lingyao
  • Zhang, Weihua
  • Zhang, Xinyuan
  • Zhao, Jinghua
  • Zhao, Wei|||0000-0002-4839-6791
  • Zhou, Wei
  • Zimmermann, Martina E.|||0000-0002-6916-4404
  • Zoledziewska, Magdalena|||0000-0002-3033-6133
  • Adair, Linda S.
  • Adams, Hieab H. H.|||0000-0003-3687-2508
  • Aguilar-Salinas, Carlos Alberto
  • Al-Mulla, Fahd|||0000-0001-5409-3829
  • Arnett, Donna|||0000-0003-2219-657X
  • Asselbergs, Folkert W.|||0000-0002-1692-8669
  • Åsvold, Bjørn Olav|||0000-0003-3837-2101
  • Attia, John Richard
  • Banas, Bernhard|||0000-0003-2076-2195
  • Bandinelli, Stefania|||0000-0002-6491-0850
  • Bennett, David Alan
  • Bergler, Tobias
  • Bharadwaj, Dwaipayan
  • Biino, Ginevra|||0000-0002-9936-946X
  • Bisgaard, Hans
  • Boerwinkle, Eric|||0000-0001-8813-0544
  • Böger, Carsten A.
  • Bønnelykke, Klaus
  • Boomsma, Dorret I.|||0000-0002-7099-7972
  • Børglum, Anders D.|||0000-0001-8627-7219
  • Borja, Judith B.
  • Bouchard, Claude|||0000-0002-0048-491X
  • Bowden, Donald W.
  • Brandslund, Ivan
  • Brumpton, Ben
  • Buring, Julie E.
  • Caulfield, Mark|||0000-0001-9295-3594
  • Chambers, John C.
  • Chandak, Giriraj R.
  • Chanock, Stephen|||0000-0002-2324-3393
  • Chaturvedi, Nish
  • Chen, Yii Der Ida
  • Chen, Zhengming|||0000-0001-6423-105X
  • Cheng, Ching-Yu|||0000-0003-0655-885X
  • Christophersen, Ingrid E.
  • Ciullo, Marina|||0000-0002-9621-9984
  • Cole, John W.|||0000-0001-9263-8930
  • Collins, Francis S.|||0000-0002-1023-7410
  • Cooper, Richard S.
  • Cruz, Miguel
  • Cucca, Francesco|||0000-0002-7414-1995
  • Cupples, L. Adrienne
  • Cutler, Michael J.
  • Damrauer, Scott M.|||0000-0001-8009-1632
  • Dantoft, Thomas M.
  • de Borst, Gert J.
  • de Groot, Lisette C.P.G.M.|||0000-0003-2778-2789
  • De Jager, Philip L.|||0000-0002-8057-2505
  • de Kleijn, D.P.V.|||0000-0003-2714-2140
  • Janaka de Silva, H.
  • Dedoussis, George V.
  • den Hollander, Anneke I.
  • Du, Shufa
  • Easton, Douglas F.|||0000-0003-2444-3247
  • Elders, Petra J. M.
  • Eliassen, A. Heather Heather
  • Ellinor, Patrick T.
  • Elmståhl, Sölve
  • Erdmann, Jeanette|||0000-0002-4486-6231
  • Evans, Michele K.
  • Fatkin, Diane
  • Feenstra, Bjarke|||0000-0003-1478-649X
  • Feitosa, Mary|||0000-0002-0933-2410
  • Ferrucci, Luigi
  • Ford, Ian
  • Fornage, Myriam|||0000-0003-0677-8158
  • Franke, Andre|||0000-0003-1530-5811
  • Franks, Paul W.|||0000-0002-0520-7604
  • Freedman, Barry I.|||0000-0003-0275-5530
  • Gasparini, Paolo
  • Gieger, Christian|||0000-0001-6986-9554
  • Girotto, Giorgia|||0000-0003-4507-6589
  • Goddard, Michael E.
  • Golightly, Yvonne M.
  • Gonzalez-Villalpando, Clicerio
  • Gordon-Larsen, P.
  • Grallert, H.
  • Grant, Struan F. A.|||0000-0003-2025-5302
  • Grarup, Niels|||0000-0001-5526-1070
  • Griffiths, L.
  • Gudnason, V.
  • Haiman, C.
  • Hakonarson, Hakon|||0000-0003-2814-7461
  • Hansen, Torben|||0000-0001-8748-3831
  • Hartman, C.A.
  • Hattersley, A.T.
  • Hayward, Caroline|||0000-0002-9405-9550
  • Heckbert, S.R.
  • Heng, C.K.
  • Hengstenberg, C.
  • Hewitt, Alex W.|||0000-0002-5123-5999
  • Hishigaki, H.
  • Hoyng, C.B.
  • Huang, Paul L.
  • Huang, W.
  • Hunt, S.C.
  • Hveem, K.
  • Hyppönen, E.
  • Iacono, William
  • Ichihara, S.
  • Ikram, M.A.
  • Isasi, C.R.
  • Jackson, R.D.
  • Jarvelin, Marjo-Riitta|||0000-0002-2149-0630
  • Jin, Zi-Bing
  • Jöckel, K.H.
  • Joshi, P.K.
  • Jousilahti, P.
  • Jukema, J.W.
  • Kähönen, M.
  • Kamatani, Yoichiro|||0000-0001-8748-5597
  • Kang, K.D.
  • Kaprio, Jaakko|||0000-0002-3716-2455
  • Kardia, S.L.R.
  • Karpe, F.
  • Kato, N.
  • Kee, F.
  • Kessler, T.
  • Khera, Amit V.
  • Khor, C.C.
  • Kiemeney, Lambertus A.
  • Kim, B.J.
  • Kim, E.K.
  • Kim, H.L.
  • Kirchhof, P.
  • Kivimaki, Mika|||0000-0002-4699-5627
  • Koh, W.P.
  • Koistinen, H.A.
  • Kolovou, G.D.
  • Kooner, J.S.
  • Kooperberg, C.
  • Köttgen, A.
  • Kovacs, P.
  • Kraaijeveld, A.
  • Kraft, Peter
  • Krauss, R.M.
  • Kumari, M.
  • Kutalik, Zoltan|||0000-0001-8285-7523
  • Laakso, Markku|||0000-0002-3394-7749
  • Lange, Leslie A.
  • Langenberg, C.
  • Launer, L.J.
  • Le Marchand, L.
  • Lee, H.
  • Lee, N.R.
  • Lehtimäki, T.
  • Li, H.
  • Li, L.
  • Lieb, Wolfgang|||0000-0003-2544-4460
  • Lin, X.
  • Lind, Lars
  • Linneberg, Allan|||0000-0002-0994-0184
  • Liu, Ching-Ti
  • Liu, Jianjun|||0000-0002-3255-3019
  • Loeffler, Markus
  • London, Barry
  • Lubitz, Steven A.
  • Lye, Stephen J.
  • Mackey, David A.
  • Mägi, Reedik
  • Magnusson, Patrik K. E.|||0000-0002-7315-7899
  • Marcus, Gregory M.|||0000-0001-5197-7696
  • Vidal, Pedro M.
  • Martin, Nicholas G.|||0000-0003-4069-8020
  • März, Winfried|||0000-0001-6083-8946
  • Matsuda, Fumihiko
  • McGarrah, Robert W.
  • McGue, Matt|||0000-0002-5580-1433
  • McKnight, Amy Jayne|||0000-0002-7482-709X
  • Medland, Sarah Elizabeth|||0000-0003-1382-380X
  • Mellström, Dan|||0000-0003-2761-3723
  • Metspalu, Andres|||0000-0002-3718-796X
  • Mitchell, Braxton|||0000-0003-4920-4744
  • Mitchell, Paul
  • Mook-Kanamori, Dennis O.
  • Morris, Andrew D.
  • Mucci, Lorelei A.
  • Munroe, Patricia B.|||0000-0002-4176-2947
  • Nalls, Mike A.
  • Nazarian, Saman
  • Nelson, Amanda E.
  • Neville, Matt J.|||0000-0002-6004-5433
  • Newton-Cheh, Christopher
  • Nielsen, Christopher S.
  • Nöthen, Markus M.|||0000-0002-8770-2464
  • Ohlsson, Claes|||0000-0002-9633-2805
  • Oldehinkel, Albertine J.|||0000-0003-3925-3913
  • Orozco, Lorena|||0000-0002-5801-9180
  • Pahkala, Katja
  • Pajukanta, Päivi
  • Palmer, Colin N. A.
  • Parra, Esteban J.|||0000-0002-2057-8577
  • Pattaro, Cristian|||0000-0002-4119-0109
  • Pedersen, Oluf
  • Pennell, Craig E.|||0000-0002-0937-6165
  • Penninx, Brenda W. J. H.
  • Pérusse, Louis|||0000-0001-6440-9698
  • Peters, Annette|||0000-0001-6645-0985
  • Peyser, Patricia A.
  • Porteous, David J.|||0000-0003-1249-6106
  • Posthuma, Danielle|||0000-0001-7582-2365
  • Power, Chris
  • Pramstaller, Peter P.
  • Province, Michael A.|||0000-0001-6102-774X
  • Qi, Qibin
  • Qu, Jia
  • Rader, Daniel J.
  • Raitakari, Olli T.
  • Ralhan, Sarju
  • Rallidis, Loukianos S.
  • Rao, Dabeeru C.
  • Redline, Susan
  • Reilly, Dermot F.
  • Reiner, Alexander P.
  • Rhee, Sang Youl|||0000-0003-0119-5818
  • Ridker, Paul M.
  • Rienstra, Michiel|||0000-0002-2581-070X
  • Ripatti, Samuli|||0000-0002-0504-1202
  • Ritchie, Marylyn D.|||0000-0002-1208-1720
  • Roden, Dan M.
  • Rosendaal, Frits|||0000-0003-2558-7496
  • Rotter, Jerome I.|||0000-0001-7191-1723
  • Rudan, Igor|||0000-0001-6993-6884
  • Rutters, Femke
  • Sabanayagam, Charumathi|||0000-0002-4042-4719
  • Saleheen, Danish|||0000-0001-6193-020X
  • Salomaa, Veikko|||0000-0001-7563-5324
  • Samani, Nilesh J.
  • Sanghera, Dharambir K.
  • Sattar, Naveed|||0000-0002-1604-2593
  • Schmidt, Börge
  • Schmidt, Helena|||0000-0001-9773-9992
  • Schmidt, Reinhold
  • Schulze, Matthias B.
  • Schunkert, Heribert|||0000-0001-6428-3001
  • Scott, Laura J.|||0000-0002-4886-5084
  • Scott, Rodney J.|||0000-0001-7724-3404
  • Sever, Peter
  • Shiroma, Eric J.
  • Shoemaker, M. Benjamin
  • Shu, Xiao-Ou
  • Simonsick, Eleanor M.
  • Sims, Mario
  • Singh, Jai Rup
  • Singleton, Andrew B.|||0000-0001-5606-700X
  • Sinner, Moritz F.
  • Smith, J. Gustav
  • Snieder, Harold|||0000-0003-1949-2298
  • Spector, Tim|||0000-0002-9795-0365
  • Stampfer, Meir J.
  • Stark, Klaus J.
  • Strachan, David P.
  • 't Hart, Leen M.
  • Tabara, Yasuharu
  • Tang, Hua
  • Tardif, J.C.
  • Thanaraj, T.A.
  • Timpson, N.J.
  • Tönjes, A.
  • Tremblay, A.
  • Tuomi, T.
  • Tuomilehto, J.
  • Tusié-Luna, M.T.
  • Uitterlinden, André G.|||0000-0002-7276-3387
  • van Dam, Rob M.
  • van der Harst, Pim|||0000-0002-2713-686X
  • Van der Velde, Nathalie
  • van Duijn, Cornelia M.|||0000-0002-2374-9204
  • van Schoor, N.M.
  • Vitart, Veronique|||0000-0002-4991-3797
  • Völker, U.
  • Vollenweider, P.
  • Völzke, Henry|||0000-0001-7003-399X
  • Wacher-Rodarte, N.H.
  • Walker, M.
  • Wang, Y.X.
  • Wareham, N.J.
  • Watanabe, R.M.
  • Watkins, Hugh
  • Weir, D.R.
  • Werge, Thomas M.
  • Widen, E.
  • Wilkens, Lynne R.
  • Willemsen, Gonneke|||0000-0003-3755-0236
  • Willett, Walter C.
  • Wilson, James F.|||0000-0001-5751-9178
  • Wong, Tien-Yin
  • Woo, Jeong-Taek|||0000-0001-9201-0713
  • Wright, Alan F.
  • Wu, Jer-Yuarn
  • Xu, Huichun|||0000-0001-8118-9607
  • Yajnik, Chittaranjan S.
  • Yokota, Mitsuhiro
  • Yuan, Jian-Min|||0000-0002-4620-3108
  • Zeggini, Eleftheria|||0000-0003-4238-659X
  • Zemel, Babette S.
  • Zheng, Wei|||0000-0003-1226-070X
  • Zhu, X.|||0000-0003-0037-411X
  • Zmuda, Joseph M.
  • Zonderman, Alan B.|||0000-0002-6523-4778
  • Zwart, John-Anker|||0000-0001-5721-0154
  • Croteau-Chonka, Damien
  • Vonk, Judith M.
  • Le Marchand, Loic
  • Chasman, Daniel I.|||0000-0003-3357-0862
  • Cho, Yoon Shin
  • Heid, Iris M.
  • McCarthy, Mark I.
  • Ng, Maggie C. Y.
  • O'Donnell, Christopher J.
  • Rivadeneira, Fernando|||0000-0001-9435-9441
  • Thorsteinsdottir, Unnur
  • Sun, Yan V.|||0000-0002-2838-1824
  • Tai, E. Shyong
  • Boehnke, Michael|||0000-0002-6442-7754
  • Deloukas, Panos|||0000-0001-9251-070X
  • Justice, Anne E.
  • Lindgren, Cecilia M.
  • Loos, Ruth J. F.|||0000-0002-8532-5087
  • Mohlke, Karen L.|||0000-0001-6721-153X
  • North, Kari E.
  • Stefánsson, Kári|||0000-0003-1676-864X
  • Walters, Robin G.|||0000-0002-9179-0321
  • Winkler, Thomas W.|||0000-0003-0292-5421
  • Young, Kristin L.|||0000-0003-0070-6145
  • Loh, Po-Ru
  • Yang, Jian|||0000-0003-4800-832X
  • Esko, Tõnu
  • Assimes, Themistocles|||0000-0003-2349-0009
  • Auton, Adam
  • Abecasis, Goncalo
  • Willer, Cristen J.|||0000-0001-5645-4966
  • Locke, Adam E.|||0000-0001-6227-198X
  • Berndt, Sonja
  • Lettre, Guillaume
  • Frayling, Timothy M.
  • Okada, Yukinori|||0000-0002-0311-8472
  • Wood, Andrew R.|||0000-0003-1726-948X
  • Visscher, PM.|||0000-0002-2143-8760
  • Hirschhorn, Joel N.|||0000-0002-1650-7901
Common single-nucleotide polymorphisms (SNPs) are predicted to collectively explain 40-50% of phenotypic variation in human height, but identifying the specific variants and associated regions requires huge sample sizes. Here, using data from a genome-wide association study of 5.4 million individuals of diverse ancestries, we show that 12,111 independent SNPs that are significantly associated with height account for nearly all of the common SNP-based heritability. These SNPs are clustered within 7,209 non-overlapping genomic segments with a mean size of around 90 kb, covering about 21% of the genome. The density of independent associations varies across the genome and the regions of increased density are enriched for biologically relevant genes. In out-of-sample estimation and prediction, the 12,111 SNPs (or all SNPs in the HapMap 3 panel) account for 40% (45%) of phenotypic variance in populations of European ancestry but only around 10-20% (14-24%) in populations of other ancestries. Effect sizes, associated regions and gene prioritization are similar across ancestries, indicating that reduced prediction accuracy is likely to be explained by linkage disequilibrium and differences in allele frequency within associated regions. Finally, we show that the relevant biological pathways are detectable with smaller sample sizes than are needed to implicate causal genes and variants. Overall, this study provides a comprehensive map of specific genomic regions that contain the vast majority of common height-associated variants. Although this map is saturated for populations of European ancestry, further research is needed to achieve equivalent saturation in other ancestries.